(JNJ) Johnson & Johnson - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US4781601046
Stock:
Total Rating 68
Risk 94
Buy Signal 0.69
| Risk 5d forecast | |
|---|---|
| Volatility | 16.5% |
| Relative Tail Risk | -3.35% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 2.08 |
| Alpha | 48.33 |
| Character TTM | |
|---|---|
| Beta | 0.110 |
| Beta Downside | 0.537 |
| Drawdowns 3y | |
|---|---|
| Max DD | 15.95% |
| CAGR/Max DD | 1.31 |
EPS (Earnings per Share)
Revenue
Description: JNJ Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income: 26.80b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA -0.14 > 1.0 |
| NWC/Revenue: 1.59% < 20% (prev 6.27%; Δ -4.68% < -1%) |
| CFO/TA 0.12 > 3% & CFO 24.53b > Net Income 26.80b |
| Net Debt (28.22b) to EBITDA (39.85b): 0.71 < 3 |
| Current Ratio: 1.03 > 1.5 & < 3 |
| Outstanding Shares: last quarter (2.44b) vs 12m ago 0.49% < -2% |
| Gross Margin: 72.78% > 18% (prev 0.69%; Δ 7209 % > 0.5%) |
| Asset Turnover: 49.66% > 50% (prev 49.32%; Δ 0.35% > 0%) |
| Interest Coverage Ratio: 33.55 > 6 (EBITDA TTM 39.85b / Interest Expense TTM 971.0m) |
Altman Z'' 5.37
| A: 0.01 (Total Current Assets 55.62b - Total Current Liabilities 54.13b) / Total Assets 199.21b |
| B: 0.85 (Retained Earnings 168.98b / Total Assets 199.21b) |
| C: 0.17 (EBIT TTM 32.58b / Avg Total Assets 189.66b) |
| D: 1.34 (Book Value of Equity 157.17b / Total Liabilities 117.67b) |
| Altman-Z'' Score: 5.37 = AAA |
Beneish M -3.11
| DSRI: 0.86 (Receivables 17.18b/18.93b, Revenue 94.19b/88.82b) |
| GMI: 0.95 (GM 72.78% / 69.07%) |
| AQI: 1.05 (AQ_t 0.60 / AQ_t-1 0.58) |
| SGI: 1.06 (Revenue 94.19b / 88.82b) |
| TATA: 0.01 (NI 26.80b - CFO 24.53b) / TA 199.21b) |
| Beneish M-Score: -3.11 (Cap -4..+1) = AA |
What is the price of JNJ shares?
As of February 27, 2026, the stock is trading at USD 245.17 with a total of 7,696,555 shares traded.
Over the past week, the price has changed by -0.87%, over one month by +10.51%, over three months by +17.92% and over the past year by +53.45%.
Over the past week, the price has changed by -0.87%, over one month by +10.51%, over three months by +17.92% and over the past year by +53.45%.
Is JNJ a buy, sell or hold?
Johnson & Johnson has received a consensus analysts rating of 3.75.
Therefor, it is recommend to hold JNJ.
- StrongBuy: 7
- Buy: 4
- Hold: 13
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the JNJ price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 232.5 | -5.2% |
| Analysts Target Price | 232.5 | -5.2% |
JNJ Fundamental Data Overview February 21, 2026
P/E Trailing = 22.2241
P/E Forward = 21.097
P/S = 6.3171
P/B = 7.1948
P/EG = 1.3185
Revenue TTM = 94.19b USD
EBIT TTM = 32.58b USD
EBITDA TTM = 39.85b USD
Long Term Debt = 39.44b USD (from longTermDebt, last quarter)
Short Term Debt = 8.49b USD (from shortTermDebt, last quarter)
Debt = 47.93b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 28.22b USD (from netDebt column, last quarter)
Enterprise Value = 636.97b USD (595.03b + Debt 47.93b - CCE 5.99b)
Interest Coverage Ratio = 33.55 (Ebit TTM 32.58b / Interest Expense TTM 971.0m)
EV/FCF = 32.34x (Enterprise Value 636.97b / FCF TTM 19.70b)
FCF Yield = 3.09% (FCF TTM 19.70b / Enterprise Value 636.97b)
FCF Margin = 20.91% (FCF TTM 19.70b / Revenue TTM 94.19b)
Net Margin = 28.46% (Net Income TTM 26.80b / Revenue TTM 94.19b)
Gross Margin = 72.78% ((Revenue TTM 94.19b - Cost of Revenue TTM 25.64b) / Revenue TTM)
Gross Margin QoQ = 86.37% (prev 69.56%)
Tobins Q-Ratio = 3.20 (Enterprise Value 636.97b / Total Assets 199.21b)
Interest Expense / Debt = 0.92% (Interest Expense 441.0m / Debt 47.93b)
Taxrate = 17.73% (5.78b / 32.58b)
NOPAT = 26.80b (EBIT 32.58b * (1 - 17.73%))
Current Ratio = 1.03 (Total Current Assets 55.62b / Total Current Liabilities 54.13b)
Debt / Equity = 0.59 (Debt 47.93b / totalStockholderEquity, last quarter 81.54b)
Debt / EBITDA = 0.71 (Net Debt 28.22b / EBITDA 39.85b)
Debt / FCF = 1.43 (Net Debt 28.22b / FCF TTM 19.70b)
Total Stockholder Equity = 79.35b (last 4 quarters mean from totalStockholderEquity)
RoA = 14.13% (Net Income 26.80b / Total Assets 199.21b)
RoE = 33.78% (Net Income TTM 26.80b / Total Stockholder Equity 79.35b)
RoCE = 27.43% (EBIT 32.58b / Capital Employed (Equity 79.35b + L.T.Debt 39.44b))
RoIC = 20.85% (NOPAT 26.80b / Invested Capital 128.54b)
WACC = 5.91% (E(595.03b)/V(642.96b) * Re(6.32%) + D(47.93b)/V(642.96b) * Rd(0.92%) * (1-Tc(0.18)))
Discount Rate = 6.32% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 33.33 | Cagr: 0.17%
[DCF] Terminal Value 86.29% ; FCFF base≈19.04b ; Y1≈19.00b ; Y5≈20.01b
[DCF] Fair Price = 235.6 (EV 596.09b - Net Debt 28.22b = Equity 567.86b / Shares 2.41b; r=5.91% [WACC]; 5y FCF grow -0.87% → 2.90% )
EPS Correlation: 14.01 | EPS CAGR: -2.16% | SUE: 0.0 | # QB: 0
Revenue Correlation: 11.28 | Revenue CAGR: 1.27% | SUE: 1.56 | # QB: 1
EPS next Quarter (2026-03-31): EPS=2.70 | Chg7d=+0.015 | Chg30d=-0.062 | Revisions Net=+0 | Analysts=17
EPS current Year (2026-12-31): EPS=11.53 | Chg7d=-0.001 | Chg30d=+0.032 | Revisions Net=+7 | Growth EPS=+6.9% | Growth Revenue=+6.8%
EPS next Year (2027-12-31): EPS=12.54 | Chg7d=-0.002 | Chg30d=+0.125 | Revisions Net=+12 | Growth EPS=+8.8% | Growth Revenue=+5.3%
[Analyst] Revisions Ratio: +0.00 (7 Up / 7 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 3.5% (Discount Rate 7.9% - Earnings Yield 4.5%)
[Growth] Growth Spread = +4.4% (Analyst 7.9% - Implied 3.5%)
P/E Forward = 21.097
P/S = 6.3171
P/B = 7.1948
P/EG = 1.3185
Revenue TTM = 94.19b USD
EBIT TTM = 32.58b USD
EBITDA TTM = 39.85b USD
Long Term Debt = 39.44b USD (from longTermDebt, last quarter)
Short Term Debt = 8.49b USD (from shortTermDebt, last quarter)
Debt = 47.93b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 28.22b USD (from netDebt column, last quarter)
Enterprise Value = 636.97b USD (595.03b + Debt 47.93b - CCE 5.99b)
Interest Coverage Ratio = 33.55 (Ebit TTM 32.58b / Interest Expense TTM 971.0m)
EV/FCF = 32.34x (Enterprise Value 636.97b / FCF TTM 19.70b)
FCF Yield = 3.09% (FCF TTM 19.70b / Enterprise Value 636.97b)
FCF Margin = 20.91% (FCF TTM 19.70b / Revenue TTM 94.19b)
Net Margin = 28.46% (Net Income TTM 26.80b / Revenue TTM 94.19b)
Gross Margin = 72.78% ((Revenue TTM 94.19b - Cost of Revenue TTM 25.64b) / Revenue TTM)
Gross Margin QoQ = 86.37% (prev 69.56%)
Tobins Q-Ratio = 3.20 (Enterprise Value 636.97b / Total Assets 199.21b)
Interest Expense / Debt = 0.92% (Interest Expense 441.0m / Debt 47.93b)
Taxrate = 17.73% (5.78b / 32.58b)
NOPAT = 26.80b (EBIT 32.58b * (1 - 17.73%))
Current Ratio = 1.03 (Total Current Assets 55.62b / Total Current Liabilities 54.13b)
Debt / Equity = 0.59 (Debt 47.93b / totalStockholderEquity, last quarter 81.54b)
Debt / EBITDA = 0.71 (Net Debt 28.22b / EBITDA 39.85b)
Debt / FCF = 1.43 (Net Debt 28.22b / FCF TTM 19.70b)
Total Stockholder Equity = 79.35b (last 4 quarters mean from totalStockholderEquity)
RoA = 14.13% (Net Income 26.80b / Total Assets 199.21b)
RoE = 33.78% (Net Income TTM 26.80b / Total Stockholder Equity 79.35b)
RoCE = 27.43% (EBIT 32.58b / Capital Employed (Equity 79.35b + L.T.Debt 39.44b))
RoIC = 20.85% (NOPAT 26.80b / Invested Capital 128.54b)
WACC = 5.91% (E(595.03b)/V(642.96b) * Re(6.32%) + D(47.93b)/V(642.96b) * Rd(0.92%) * (1-Tc(0.18)))
Discount Rate = 6.32% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 33.33 | Cagr: 0.17%
[DCF] Terminal Value 86.29% ; FCFF base≈19.04b ; Y1≈19.00b ; Y5≈20.01b
[DCF] Fair Price = 235.6 (EV 596.09b - Net Debt 28.22b = Equity 567.86b / Shares 2.41b; r=5.91% [WACC]; 5y FCF grow -0.87% → 2.90% )
EPS Correlation: 14.01 | EPS CAGR: -2.16% | SUE: 0.0 | # QB: 0
Revenue Correlation: 11.28 | Revenue CAGR: 1.27% | SUE: 1.56 | # QB: 1
EPS next Quarter (2026-03-31): EPS=2.70 | Chg7d=+0.015 | Chg30d=-0.062 | Revisions Net=+0 | Analysts=17
EPS current Year (2026-12-31): EPS=11.53 | Chg7d=-0.001 | Chg30d=+0.032 | Revisions Net=+7 | Growth EPS=+6.9% | Growth Revenue=+6.8%
EPS next Year (2027-12-31): EPS=12.54 | Chg7d=-0.002 | Chg30d=+0.125 | Revisions Net=+12 | Growth EPS=+8.8% | Growth Revenue=+5.3%
[Analyst] Revisions Ratio: +0.00 (7 Up / 7 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 3.5% (Discount Rate 7.9% - Earnings Yield 4.5%)
[Growth] Growth Spread = +4.4% (Analyst 7.9% - Implied 3.5%)